Skip to main content
. 2023 Feb 17;6(2):76–86. doi: 10.1093/abt/tbad002

Figure 3.

Figure 3

SARS-CoV-2 neutralizing mAbs. (A) Neutralization activities of nAbs against SARS-CoV-2 pseudovirus. SARS-CoV-2 pseudovirus were incubated with 3-fold serial dilutions of nAbs, with the highest concentration set to 10 μg/ml. The same experiments were done twice independently. IC50 were determined by a four-parameter logistic model. (B) Neutralization profiles of the nine purified nAbs against SARS-CoV-2 live virus. nAbs with 5-fold serial dilutions were incubated with the same volume of approximately 100 PFU of SARS-CoV-2, with the highest concentration set to 10 μg/ml. The mixtures were then added to the Vero cell monolayers. The same experiments were done twice independently. The PRNT50 values were determined using non-linear regression analysis. The positive control antibody is HLX70, and US Food and Drug Administration has approved the application for a phase I clinical trial with HLX70.